{
  "id" : "mets_hat",
  "algorithm" : "eod_public",
  "version" : "3.2",
  "name" : "EOD Mets",
  "title" : "EOD Mets",
  "notes" : "**Note 1:** **Pleural effusion** \n* A physician’s statement of positive (malignant) pleural effusion or a positive cytology confirming a malignant pleural effusion must be used to code 05. \n  * If the physician feels the pleural effusion is due to tumor, despite negative cytology, the physician’s assessment can be used to code EOD Mets\n* If pleural fluid cytology is described as suspicious/suspicious for mesothelioma, code 05\n* A positive pleural effusion (code 05) should not be coded as present under the Mets at Dx-Other field. \n   * Code 0 for Mets at Dx-Other when code 05 is coded in EOD Mets.\n\n**Note 2:** **Additional data item for staging** \n* In addition to EOD Mets, the following data item is also collected to determine the results of the Pleural Effusion, which include negative, atypical, or Pleural effusion, NOS\n* Pleural effusion [NAACCR Data Item #3913]\n\n**Note 3:** **Pleural effusion with other mets** \n* If there is a malignant pleural effusion WITH other mets, code 70.",
  "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) Rusch, V.W., et al. **Malignant Plural Mesothelioma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017",
  "last_modified" : "2024-05-16T18:41:03.125Z",
  "definition" : [ {
    "key" : "eod_mets",
    "name" : "Code",
    "type" : "INPUT"
  }, {
    "key" : "description",
    "name" : "Description",
    "type" : "DESCRIPTION"
  }, {
    "key" : "eod_2018_m",
    "name" : "EOD 2018 M",
    "type" : "ENDPOINT"
  }, {
    "key" : "ss2018_m",
    "name" : "SS2018 M",
    "type" : "ENDPOINT"
  } ],
  "rows" : [ [ "00", "No distant metastasis\nUnknown if distant metastasis", "VALUE:M0", "VALUE:NONE" ], [ "05", "Malignant pleural effusion", "VALUE:M0", "VALUE:D" ], [ "10", "Distant lymph node\n- Cervical   \n- Distant lymph node(s), NOS", "VALUE:M1", "VALUE:D" ], [ "70", "Contralateral lung\nContralateral pleura/chest wall (discontinuous involvement)\nLung (discontinuous ipsilateral lung tumors)\nMediastinal organs (discontinuous involvement)\nPeritoneum (discontinuous extension of tumor)\nPericardial effusion, malignant (discontinuous involvement) \nPleural effusion (malignant pleural fluid) WITH other metastases\n\nCarcinomatosis\n\nDistant metastasis WITH or WITHOUT distant lymph node(s)\n\nDistant metastasis, NOS", "VALUE:M1", "VALUE:D" ], [ "99", "Death Certificate Only", "VALUE:M0", "VALUE:U" ] ]
}